Prognostic factors in betel and tobacco related oral cancer.
暂无分享,去创建一个
R. Ralhan | M. Mathur | N. Shukla | P Pande | S Soni | J Kaur | S Agarwal | M Mathur | N K Shukla | R Ralhan | S. Soni | P. Pande | S. Agarwal | J. Kaur | J. Kaur
[1] Joseph R. Nevins,et al. The E2F transcription factor is a cellular target for the RB protein , 1991, Cell.
[2] S. Groshen,et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. , 1998, Cancer research.
[3] T. Saito,et al. Immunohistochemical analysis of cell cycle-associated proteins p16, pRb, p53, p27 and Ki-67 in oral cancer and precancer with special reference to verrucous carcinomas. , 2007, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[4] W. Benedict,et al. Altered retinoblastoma protein expression in nonsmall cell lung cancer , 1997, Cancer.
[5] H. Harada,et al. Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology , 1999, British Journal of Cancer.
[6] C. Cordon-Cardo,et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. , 1997, Cancer research.
[7] B. Wasylyk,et al. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis , 2000, The EMBO journal.
[8] R. Ralhan,et al. Prognostic significance of p53 protein overexpression in betel‐ and tobacco‐related oral oncogenesis , 1998, International journal of cancer.
[9] J. Varley,et al. Frequent alterations of cell cycle regulators in early-stage breast lesions as detected by immunohistochemistry. , 1998, British Journal of Cancer.
[10] K. Warnakulasuriya,et al. Relationship of p53 overexpression to other cell cycle regulatory proteins in oral squamous cell carcinoma. , 2007, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[11] W. Benedict,et al. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. , 1994, Journal of the National Cancer Institute.
[12] S. Shibata,et al. Expression of the Ets-1 proto-oncogene correlates with malignant potential in human astrocytic tumors. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[13] G. Hannon,et al. p53-Independent Role of MDM2 in TGF-β1 Resistance , 1998 .
[14] Taylor Murray,et al. Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.
[15] H. Dosaka-akita,et al. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. , 1996, Cancer research.
[16] Y. Eizuru,et al. Retinoblastoma protein expression and prognosis in laryngeal cancer. , 1998, Acta oto-laryngologica.
[17] R. Ralhan,et al. Overexpression of p53 protein in betel‐ and tobacco‐related human oral dysplasia and squamous‐cell carcinoma in India , 1994, International journal of cancer.
[18] R. Ralhan,et al. Expression of cyclin dependent kinase inhibitor p21waf1/cip1 in premalignant and malignant oral lesions: relationship with p53 status. , 1998, Oral oncology.
[19] R. Ralhan,et al. Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer. , 2000, The American journal of pathology.
[20] S. Girod,et al. Proliferative activity and loss of function of tumour suppressor genes as 'biomarkers' in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma. , 1998, The British journal of oral & maxillofacial surgery.
[21] J. D. Weber,et al. The ARF/p53 pathway. , 2000, Current opinion in genetics & development.
[22] M. S. Burger,et al. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. , 2000, Cancer research.
[23] M. Partridge,et al. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines , 1999, British Journal of Cancer.
[24] R. Kratzke,et al. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. , 1995, Cancer research.
[25] R. Ralhan,et al. pRb and p16 protein alterations in human oral tumorigenesis. , 1998, Oral oncology.
[26] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[27] R. Ralhan,et al. Ets‐1: a plausible marker of invasive potential and lymph node metastasis in human oral squamous cell carcinomas , 1999 .
[28] S. Ishiguro,et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. , 1997, British Journal of Cancer.
[29] W. Benedict,et al. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] A. Børresen-Dale,et al. Interaction between bcl‐2 and p21 (WAF1/CIP1) in breast carcinomas with wild‐type p53 , 1997, International journal of cancer.
[31] B. Vandenbunder,et al. Expression of the transcription factor c-Ets1 correlates with the occurrence of invasive processes during normal and pathological development. , 1994, Invasion & metastasis.
[32] R. Ralhan,et al. MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications. , 1999, Oral oncology.